Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Avadel Pharmaceuticals (AVDL)
NASDAQ:AVDL
Holding AVDL?
Track your performance easily
AVDL Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$9.41 - $19.09
Previous Close$10.11
Volume1.17M
Average Volume (3M)1.19M
Market Cap
$974.22M
Enterprise Value$910.35M
Total Cash (Recent Filing)$65.81M
Total Debt (Recent Filing)$1.94M
Price to Earnings (P/E)―
Beta0.80
Next Earnings
Mar 13, 2025EPS Estimate
-$0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.77
Shares Outstanding96,361,528
10 Day Avg. Volume1,468,553
30 Day Avg. Volume1,186,634
Standard Deviation0.24
R-Squared0.08
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)13.39
Price to Sales (P/S)7.05
Price to Cash Flow (P/CF)-35.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue6.59
Enterprise Value/Gross Profit33.57
Enterprise Value/Ebitda-15.05
Forecast
1Y Price Target
$25.75Price Target Upside149.76% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Avadel Pharmaceuticals News
PremiumCompany Announcements
Avadel Pharmaceuticals Reports Strong Growth with LUMRYZ
Bulls Say, Bears Say
Bulls Say
Financial PerformanceLUMRYZ sales were ahead of consensus and in line with the highest estimates, with spending significantly lighter than expected.
Market PositionLUMRYZ, as a once-nightly oxybate, offers a significant improvement in patient care compared to alternatives requiring a middle-of-the-night dose.
Regulatory ApprovalThe company received approval for Lumryz for the treatment of pediatric patients (7 years and older) with narcolepsy.
Bears Say
Legal UncertaintyInvestor concerns persist about an imminent court ruling regarding the original approval of LUMRYZ, reflecting uncertainty in the stock.
Management ChangesInvestors have been very nervous due to the comments from the 3Q24 print and the CCO leaving the company.
Patient DiscontinuationHigher LUMRYZ patient discontinuation rates than expected were noted, causing a negative reaction in the market.
---
Ownership Overview
11.23% Insiders
11.08% Mutual Funds
38.65% Other Institutional Investors
30.69% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
AVDL FAQ
What was Avadel Pharmaceuticals’s price range in the past 12 months?
Avadel Pharmaceuticals lowest stock price was $9.41 and its highest was $19.09 in the past 12 months.
What is Avadel Pharmaceuticals’s market cap?
Currently, no data Available
When is Avadel Pharmaceuticals’s upcoming earnings report date?
Avadel Pharmaceuticals’s upcoming earnings report date is Mar 13, 2025 which is in 82 days.
How were Avadel Pharmaceuticals’s earnings last quarter?
Avadel Pharmaceuticals released its earnings results on Nov 12, 2024. The company reported -$0.03 earnings per share for the quarter, beating the consensus estimate of -$0.082 by $0.052.
Is Avadel Pharmaceuticals overvalued?
According to Wall Street analysts Avadel Pharmaceuticals’s price is currently Undervalued.
Does Avadel Pharmaceuticals pay dividends?
Avadel Pharmaceuticals does not currently pay dividends.
What is Avadel Pharmaceuticals’s EPS estimate?
Avadel Pharmaceuticals’s EPS estimate is -$0.03.
How many shares outstanding does Avadel Pharmaceuticals have?
Avadel Pharmaceuticals has 96,361,530 shares outstanding.
What happened to Avadel Pharmaceuticals’s price movement after its last earnings report?
Avadel Pharmaceuticals reported an EPS of -$0.03 in its last earnings report, beating expectations of -$0.082. Following the earnings report the stock price went down -19.325%.
Which hedge fund is a major shareholder of Avadel Pharmaceuticals?
Among the largest hedge funds holding Avadel Pharmaceuticals’s share is Woodline Partners LP. It holds Avadel Pharmaceuticals’s shares valued at 22M.
---
Avadel Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$25.75 (149.76% Upside)
$25.75 (149.76% Upside)
Blogger Sentiment
Bullish
AVDL Sentiment 66%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 396.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $406.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.4%
Last 30 Days ▼ 5.1%
Last 30 Days ▼ 5.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-28.80%
12-Months-Change
Fundamentals
Return on Equity
-78.54%
Trailing 12-Months
Asset Growth
-22.08%
Trailing 12-Months
Company Description
Avadel Pharmaceuticals
Avadel Pharmaceuticals Plc engages in the development and commercialization of pharmaceutical products. It offers Bloxiverz, Vazculep, and Akovaz. The company was founded on December 1, 2015 and is headquartered in Dublin, Ireland.
---
AVDL Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlights significant progress and achievements, such as strong patient growth, new FDA approvals, and positive legal outcomes. However, challenges persist with patient persistency and ongoing litigation. The sentiment is overall positive, driven by consistent growth and strategic achievements, despite the noted challenges.Read More>---
AVDL Stock 12 Month Forecast
Average Price Target
$25.75
▲(149.76% Upside)
Technical Analysis
Arrowhead Pharmaceuticals
―
Assertio Therapeutics
―
Karyopharm Therapeutics
―
Durect
―
Best Analysts Covering AVDL
1 Year
1 Year Success Rate
16/25 ratings generated profit
1 Year Average Return
+60.87%
reiterated a buy rating 5 months ago
Copying Ami Fadia's trades and holding each position for 1 Year would result in 64.00% of your transactions generating a profit, with an average return of +60.87% per trade.
---